We herein present an overview of the upcoming 5th edition of the World Health Organization
Classification of Haematolymphoid Tumours focussing on lymphoid neoplasms. Myeloid …

Importance Multiple myeloma is a hematologic malignancy characterized by presence of
abnormal clonal plasma cells in the bone marrow, with potential for uncontrolled growth …

Elranatamab is a humanized B-cell maturation antigen (BCMA)-CD3 bispecific antibody. In
the ongoing phase 2 MagnetisMM-3 trial, patients with relapsed or refractory multiple …

Since the publication of the Revised European-American Classification of Lymphoid
Neoplasms in 1994, subsequent updates of the classification of lymphoid neoplasms have …

Abstract Disease Overview Multiple myeloma accounts for approximately 10% of
hematologic malignancies. Diagnosis The diagnosis requires≥ 10% clonal bone marrow …

PURPOSE Patients with newly diagnosed multiple myeloma (NDMM) show heterogeneous
outcomes, and approximately 60% of them are at intermediate-risk according to the Revised …

Multiple myeloma is a treatable, but currently incurable, hematological malignancy of
plasma cells characterized by diverse and complex tumor genetics for which precision …

Hematologic malignancies are among the most common cancers, and understanding their
incidence and death is crucial for targeting prevention, clinical practice improvement, and …

Background Bortezomib, thalidomide, and dexamethasone (VTd) plus autologous stem-cell
transplantation is standard treatment in Europe for transplant-eligible patients with newly …

The treatment of multiple myeloma (MM) continues to evolve rapidly with arrival of multiple
new drugs, and emerging data from randomized trials to guide therapy. Along the disease …